Citations

Clear

590 citation(s) found for "Ho, Ben".

Evaluating gender as a predictive marker for response to bevacizuamb (Bev) in metastatic colorectal carcinoma (mCRC): Pooled analysis of 3369 patients (pts) in the ARCAD database.
Margalit, Ofer , Harmsen, William S. , Shacham‐Shmueli, Einat , Petersen, M. , Boursi, Ben , Douillard, Jean‐Yves , Hurwitz, Herbert I. , Bokemeyer, Carsten , Kabbinavar, Fairooz F. , Gramont, Aimery de , Lenz, Heinz‐Josef , Saltz, Leonard B. , Adams, Richard , Maughan, Tim , Cutsem, Eric Van , Tebbutt, Niall C. , Shi, Qian

Mayo Clinic

Journal of Clinical Oncology | May 27, 2019 | Volume: 37 | Issue: 15_suppl | Pages: 3539-3539

10.1200/jco.2019.37.15_suppl.3539 Get It

3539 Background: Previous studies suggest a possible gender-specific response to Bev in mCRC, showing a benefit in males, while the effect in females is less significant. Therefore, we evaluated response to Bev according to gender. Methods: Data from 3369 mCRC patients enrolled on 4 first-line randomized trials testing Bev (2000-2007) were pooled. Association between gender and progression-free survival (PFS)/overall survival (OS) was evaluated by stratified Cox regression model, adjusted for potential confounders. Predictive value was evaluated by interaction (inter.) effect between gender and treatment. In a pre-planned secondary analysis, analyses were stratified using an age cut-point of 60 years (commonly used in breast cancer trials) to evaluate the possible role of menopausal-related effects. Results: OS was not statistically different between males and females (median OS [mOS], 18.8 vs. 17.6 months [mo], adjusted hazard ratio [HRadj], 0.93, 95% confidence interval [CI], 0.84-1.03, p, 0.15) in the overall population. Bev was associated with an improved mOS in males and females, with a 2.3 and 0.6 mo benefit, respectively, as well as an improved PFS. There was no statistically significant interaction effect between gender and treatment (see table). Further stratified by age (< vs. ≥ 60 years), Bev resulted in improved PFS and OS in both genders, at all ages, except for the effect in young females which did not reach statistical significance (see table). Conclusions: Our results confirmed the mOS benefit from addition of Bev to first-line chemotherapy in mCRC in both genders, although the benefit in females was < 1 month. For females under the age of 60, there are uncertainties for mOS benefit from addition of Bev and further evaluation is needed. [Table: see text]
A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with pazopanib in patients with advanced soft tissue sarcoma (STS).
Attia, Steven , Conry, Robert M. , Sankhala, Kamalesh K. , Seon, Ben K. , Alvarez, Delia, Adams, Bonne J., Theuer, Charles P. , Riedel, Richard F. , Robinson, Steven I. , Maki, Robert G.

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 10514-10514

10.1200/jco.2015.33.15_suppl.10514 Get It

Integrated Transcriptomic and Proteomic Analysis of Primary Human Umbilical Vein Endothelial Cells
Madugundu, Anil K. , Na, Chan Hyun , Nirujogi, Raja Sekhar , Renuse, Santosh , Kim, Kwang Pyo , Wilks, Christopher , Langmead, Ben , Collado‐Torres, Leonardo , Kim, Min‐Sik , Pandey, Akhilesh , Kim, Min-Sik , Pandey, Akhilesh , Pandey, Akhilesh , Kim, Kwang Pyo , Burns, Kathleen H , Ellis, Shannon , Halushka, Marc K.

Mayo Clinic

PROTEOMICS | April 15, 2019 | Volume: 19 | Issue: 15 | Pages: No page available

10.1002/pmic.201800315 | PMID 30983154 Get It

Abstract Understanding the molecular profile of every human cell type is essential for understanding its role in normal physiology and disease. Technological advancements in DNA sequencing, mass spectrometry, and computational methods allow us to carry out multiomics analyses although such approaches are not routine yet. Human umbilical vein endothelial cells (HUVECs) are a widely used model system to study pathological and physiological processes associated with the cardiovascular system. In this study, next‐generation sequencing and high‐resolution mass spectrometry to profile the transcriptome and proteome of primary HUVECs is employed. Analysis of 145 million paired‐end reads from next‐generation sequencing confirmed expression of 12 186 protein‐coding genes (FPKM ≥0.1), 439 novel long non‐coding RNAs, and revealed 6089 novel isoforms that were not annotated in GENCODE. Proteomics analysis identifies 6477 proteins including confirmation of N ‐termini for 1091 proteins, isoforms for 149 proteins, and 1034 phosphosites. A database search to specifically identify other post‐translational modifications provide evidence for a number of modification sites on 117 proteins which include ubiquitylation, lysine acetylation, and mono‐, di‐ and tri‐methylation events. Evidence for 11 “missing proteins,” which are proteins for which there was insufficient or no protein level evidence, is provided. Peptides supporting missing protein and novel events are validated by comparison of MS/MS fragmentation patterns with synthetic peptides. Finally, 245 variant peptides derived from 207 expressed proteins in addition to alternate translational start sites for seven proteins and evidence for novel proteoforms for five proteins resulting from alternative splicing are identified. Overall, it is believed that the integrated approach employed in this study is widely applicable to study any primary cell type for deeper molecular characterization.
High‐Sensitivity Cardiac Troponin After Cardiac Stress Test: A Systematic Review and Meta‐Analysis
Samaha, Eslam , Avila, Audrey, Helwani, Mohammad A. , Abdallah, Arbi Ben , Jaffe, Allan S. , Scott, Mitchell G., Nägele, Peter , Jaffe, Allan S.

Mayo Clinic

Journal of the American Heart Association | March 15, 2019 | Volume: 8 | Issue: 6 | Pages: No page available

10.1161/jaha.118.008626 | PMID 30871395 Get It

Background The recent introduction of high‐sensitivity cardiac troponin (hs‐cTn) assays has allowed clinicians to measure hs‐cTn before and after cardiac stress testing, but the hs‐cTn release pattern and potential utility in identifying inducible myocardial ischemia are unclear. We thus conducted a systematic review and meta‐analysis to improve our understanding of hs‐cTn release associated with exercise and pharmacological stress testing. Methods and Results Studies published between January 2008 and July 2016 that reported hs‐cTn change values (high‐sensitivity cardiac troponin T [hs‐cTnT] or high‐sensitivity cardiac troponin I [hs‐cTnI]) in relation to cardiac stress testing were searched and reviewed by 2 independent screeners. Primary outcomes were pooled estimates of absolute and relative hs‐cTn changes after cardiac stress test, stratified by the presence of inducible myocardial ischemia. This meta‐analysis included 11 studies (n=2432 patients). After exercise stress testing, hs‐cTnT increased by 0.5 ng/L or 11% (6 studies, n=406) and hs‐cTnI by 2.4 ng/L or 41% (4 studies, n=365) in patients with inducible myocardial ischemia versus hs‐cTnT by 1.1 ng/L or 18% (8 studies, n=629; P =0.29) and hs‐cTnI by 1.8 ng/L or 72% (4 studies, n=831; P =0.61) in patients who did not develop inducible myocardial ischemia. After pharmacological stress test, hs‐cTnT changed by −0.1 ng/L or −0.4% (6 studies, n=251) and hs‐cTnI by 2.4 ng/L or 32% (2 studies, n=108) in patients with inducible myocardial ischemia versus hs‐cTnT by 0.7 ng/L or 11% (5 studies, n=443, P =0.44) and hs‐cTnI by 1.7 ng/L or 38% (2 studies, n=116; P =0.62) in patients who did not develop inducible myocardial ischemia. Conclusions hs‐cTn rising patterns after exercise and pharmacological stress testing appear inconsistent and comparably small, and do not appear to be correlated with inducible myocardial ischemia.
Identification of high‐risk DUSP 22 ‐rearranged ALK ‐negative anaplastic large ce
Hapgood, Greg , Mottok, Anja , Lee, Derrick G. , Kridel, Robert , Villa, Diego , Gascoyne, Randy D. , Farinha, Pedro , Slack, Graham W. , Villa, Diego , Savage, Kerry J , Farinha, Pedro , Ben‐Neriah, Susana , Kridel, Robert , Sehn, Laurie H. , Connors, Joseph M. , Feldman, Andrew L. , Steidl, Christian , Scott, David W. , Savage, Kerry J.

Mayo Clinic

British Journal of Haematology | March 14, 2019 | Volume: 186 | Issue: 3 | Pages: No page available

10.1111/bjh.15860 | PMID 30873584 Get It

Association of germline variation with androgen ablation (AA) failure in advanced hormone-sensitive prostate cancer (HSPC).
Zhang, Ben Yiming, Riska, Shaun M., Lee, Adam M , Quevedo, Fernando , Costello, Brian A. , Pitot, Henry C., Monteiro, Cátia, Nogueira, Augusto, Maurício, Joaquina, Fraga, Avelino , Silva, Fernando Eduardo Calais Da, Kochuparambil, Samith T. , Mahoney, Douglas W. , McDonnell, Shannon K. , Lee, Adam M. , Ribeiro, Ricardo , Medeiros, Rui , Cerhan, James R. , Kohli, Manish

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: e16117-e16117

10.1200/jco.2015.33.15_suppl.e16117 Get It

Variation in TRMT11 gene as a prognostic marker in advanced-stage castrate-resistant prostate cancer (CRPC) patients.
Zhang, Ben Yiming, Riska, Shaun M., Ribeiro, Ricardo , Medeiros, Rui , Monteiro, Cátia, Nogueira, Augusto, Maurício, Joaquina, Fraga, Avelino , Calais-Da-Silva, Fernando, Costello, Brian A. , Dronca, Roxana , Pitot, Henry C., Moynihan, Timothy J. , Quevedo, Fernando , Mahoney, Douglas W. , Cerhan, James R. , Kohli, Manish

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: e16114-e16114

10.1200/jco.2015.33.15_suppl.e16114 Get It